MiniMed Group, Inc. (MMED) Stock: Price, Forecast & Analyst Target
MiniMed Group, Inc. (MMED) — MoonshotScore 38/100 (Weak band), calculated Nov 18, 2026. Price $16.26 (-4.30%), as of the Nov 19, 2026 trading session; market cap $4.57B.
Educational signal · not a buy or sell recommendation · How to read this
MiniMed Group, Inc. · MMED · NASDAQ · Healthcare · Medical - Equipment & Services
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · MiniMed Group (MMED)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and a strong balance sheet. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Sound; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.
- quarterly revenue $843M (Q1 FY2026, quarter ended Jul 2026)
- EPS beat 0 of the last 3 reports
- Altman Z 3.55 · Piotroski F 2
Helping: business quality, balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 38 | Weak | |
| 38 | Weak | |
| 38 | Weak | |
| 38 | Weak | |
| 38 | Weak | |
| 38 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $16.26 | |
| Change on the day | -4.30% | |
| 52-week range | $10.65–$24.43 | |
| Market capitalisation | $4.57B | — |
| Shares traded on the day | 5.87M | |
| Beta (volatility vs the S&P 500) | -3.7 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for MiniMed Group (MMED): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 15, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 13, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 13, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is MiniMed Group (MMED), and what does it report?
Short answer
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. MiniMed Group, Inc. (MMED) is listed on NASDAQ. Healthcare / Medical Equipment & Services SEC filing business address: Northridge, CA. It employs 8,000 people and is led by Que Thanh Dallara. In Q1 FY2026 it reported revenue of $843M and net income of $0. The market values it at $4.57B.
What do the latest results show for MiniMed Group (MMED)?
Short answer · as of
The most recent reported quarter, Q1 FY2026, carried revenue of $843M. Against analyst estimates the company has EPS beat 0 of the last 3 reports.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Apr 30, 2026 | Not available | Not available | Not available | Not available |
| Jan 31, 2026 | Not available | Not available | Not available | Not available |
| Oct 31, 2025 | Not available | Not available | Not available | Not available |
| Jul 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2026 | $843M | $0 | — |
| Q4 FY2025 | $837M | -$183M | -$0.68 (diluted) |
| Q3 FY2025 | $790M | -$119M | -$0.42 (diluted) |
| Q2 FY2025 | $752M | -$27M | -$0.10 (diluted) |
What are the financial strengths and risks for MiniMed Group (MMED)?
Short answer · as of
Cash and short-term investments were $0.00 at the Jul 31, 2026 balance-sheet date. This figure does not establish a cash runway. The MoonshotScore pillars rate business quality, balance-sheet strength, positive momentum as strengths. The distress and quality screens read Altman Z 3.55 · Piotroski F 2. Trailing ratios: ROE -9.1% · ROA -7.0% · current ratio 1.81 · earnings yield -6.3% · free-cash-flow yield -6.0%.
Data-derived red flags
- Negative return on equity (-9.1%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at MiniMed Group (MMED)?
Short answer · as of
Analyst estimates on file carry FY2027 revenue $3.44B · EPS 0.69 · 11 analysts. Current published price targets run low $16.00 · high $30.00 · consensus $25.73 · median $28.00 against a quoted price of $16.26 (as of Nov 19, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does MiniMed Group compare with its peers?
Short answer
MiniMed Group's score ranks 3rd of 8 in the bounded comparison shown, against 7 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $23.75 Nov 18, 2026 | $3.81B | 81 5-pillar Nov 18, 2026 | |
| $41.98 Nov 18, 2026 | $5.28B | 78 5-pillar Nov 18, 2026 | |
| MiniMed Group (MMED) — this page | $16.26 | $4.57B | 38 |
| $18.97 Nov 18, 2026 | $105M | 37 5-pillar Nov 18, 2026 | |
| $17.05 Nov 18, 2026 | $4.00B | 31 5-pillar Nov 18, 2026 | |
| $14.33 Nov 18, 2026 | $779M | 30 5-pillar Nov 18, 2026 | |
| $6.82 Nov 18, 2026 | $366M | 28 5-pillar Nov 18, 2026 | |
| $4.45 Nov 18, 2026 | $81.6M | 20 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $16.00 – $30.00
- Consensus target
- $25.73
- Median target
- $28.00
- Revenue estimate
- $3.44B
- EPS estimate
- $0.69
Consensus record · Captured .
Measured against a quoted price of $16.26 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Oct 28, 2026
- Transactions
- 34
- Identified insiders
- 15
- Purchases
- 0
- Sales
- 0
- Other transactions
- 34
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MMED in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported MMED in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about MiniMed Group (MMED)?
What Investors Ask About MiniMed Group (MMED) — Healthcare
These answers are editorial: 1 of these 9 answers is drawn from the MMED research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for MMED?
MMED carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. MiniMed Group, Inc. specializes in medical technologies for diabetes management, including insulin pumps and continuous glucose monitoring systems.
Is MMED a good stock to buy?
Stock Expert AI does not rate MMED buy, sell or hold. MiniMed Group, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the MMED stock price today?
The last price recorded for MiniMed Group, Inc. (MMED), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MMED price target?
The analyst consensus price target for MiniMed Group, Inc. (MMED), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What does MiniMed Group, Inc. Common Stock do?
MiniMed Group, Inc. specializes in the design, production, and distribution of advanced medical technologies specifically for diabetes management. Its core offerings include a comprehensive suite of tools such as state-of-the-art insulin pumps, which facilitate precise insulin delivery, and continuous glucose monitoring (CGM) systems that provide real-time blood glucose data.
What are the key factors to evaluate for MMED?
MiniMed Group, Inc. (MMED) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Dividend Policy: No dividend yield, consistent with a growth-oriented company reinvesting earnings into R&D and market expansion. Not financial advice.
How frequently does MMED data refresh on this page?
MMED's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven MMED's recent stock price performance?
MiniMed Group, Inc. (MMED) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive portfolio of diabetes management solutions, including insulin pumps and CGM systems. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MMED overvalued or undervalued right now?
MiniMed Group, Inc. (MMED) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 32 figures on this page — 1 from SEC filings and earnings calls, 23 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com